Description
Market Report Coverage – Non-Invasive Liquid Biopsy
Market Segmentation
• Offering– Products (Kits and Assays) and Services
• Sample – Stool, Urine, Saliva, and Other Samples
• Application – Oncology, Reproductive Health, Metabolic Disorders, and Other Applications
• Technology – Polymerase Chain Reaction (RT-PCR and dPCR), Sequencing (NGS and Sanger Sequencing), Microarray, and Other Technologies
• End User – Hospitals and Diagnostic Laboratories, Academic and Research Institutions, and Other End Users
Regional Segmentation
• North America – U.S., and Canada
• Europe – Germany, U.K., France, Italy, Spain, Netherlands, and Rest-of-Europe
• Asia-Pacific – China, Japan, India, South Korea, Australia, Singapore, and Rest-of-Asia-Pacific
• Latin America – Brazil, Mexico, and Rest-of-Latin America
• Rest-of-the-World
Market Growth Drivers
• Global Increase in Cancer Prevalence
• Increasing Government Funding for Healthcare
• Rise in Patient Preference for Non-Invasive Cancer Diagnosis
• Growing Prominence of Precision Medicine in the Oncology Ecosystem
Market Challenges
• False Negatives and Positives
• Lack of Favorable Reimbursement Policies
• Existing Diagnostic Confidence on Conventional Tissue-Based Biopsies
Market Opportunities
• Amalgamation of Artificial Intelligence (AI) with Non-Invasive Liquid Biopsy
• Massive Scope for the Adoption of Non-Invasive Liquid Biopsy Tests in the Emerging Markets
Key Companies Profiled
Bio-Techne Corporation, Endress + Hauser Group, Exact Sciences Corporation, Lonza Group AG, MDxHealth, Merck KGaA, MutantDx, Norgen Biotek Corp, Nucleix Ltd., Oasis Diagnostics Corporation, OraSure Technologies, Inc., PerkinElmer Inc., Predicine, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Zymo Research Corporation
Key Questions Answered in this Report:
• How is non-invasive liquid biopsy revolutionizing the field of oncology, reproductive health, and metabolic disorders?
• What are the major market drivers, challenges, and opportunities in the global non-invasive liquid biopsy market?
• What are the underlying structures resulting in the emerging trends within the global non-invasive liquid biopsy market?
• How did the COVID-19 pandemic impact the global non-invasive liquid biopsy ecosystem?
• What are the key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to the use of non-invasive liquid biopsy?
• What are the potential entry barriers, which are expected to be faced by the companies willing to enter a particular region?
• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:
o Offering (products and services)
o Sample (stool, urine, saliva, and other samples)
o Technology (sequencing, polymerase chain reaction (PCR), microarray, and other technologies)
o Application (oncology, reproductive health, metabolic disorders, and other applications)
o End User (academic and research institutions, hospitals and diagnostic laboratories, and other end users)
o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
• What are the growth opportunities for the non-invasive liquid biopsy companies in the region of their operation?
• Who are the leading players with significant offerings in the global non-invasive liquid biopsy market?
• Which companies are anticipated to be highly disruptive in the future, and why?
Market Overview
Our healthcare experts have found the non-invasive liquid biopsy industry to be one of the most rapidly evolving and dynamic markets, and the global market for non-invasive liquid biopsy is predicted to grow at a CAGR of 20.38% over the forecast period 2021-2031. The market is driven by certain factors, which include a global increase in cancer prevalence, increasing government funding for healthcare, rise in patient preference for non-invasive cancer diagnosis, and growing prominence of precision medicine in the oncology ecosystem.
The market is favored by the developments in the field of cancer molecular diagnostic testing and its attributes such as non-invasive liquid biopsy. Currently, the non-invasive liquid biopsy industry is witnessing an upsurge due to the global increase in cancer prevalence, increasing government funding for healthcare, rise in patient preference for non-invasive cancer diagnosis, and growing prominence of precision medicine in the oncology ecosystem.
Furthermore, biotechnology companies are focusing on the development of robust non-invasive liquid biopsy solutions for a wide range of applications, including oncology, reproductive health, metabolic disorders, to support clinicians to unravel insights pertaining to the analysis of genetic alterations present in the circulating biomarkers in samples such as stool, urine, and saliva. The development of non-invasive liquid biopsy products and services enabled clinicians to offer early cancer screening and diagnosis to patients, further improving survival rates.
Within the research report, the market is segmented on the basis of offering, sample, application, technology, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the number of cases associated with cancer has created a buzz among the biotechnology companies to further invest in the development of innovative cancer diagnostics, including non-invasive liquid biopsy, further aiding physicians to offer value-based clinical outcomes to patients. Due to the established presence of Exact Sciences Corporation in the U.S. market, offering its proprietary Cologuard test, the company has been the leading player in the non-invasive liquid biopsy ecosystem.
On the basis of region, North America holds the largest share of the non-invasive liquid biopsy market due to high infusion of funding from the government organizations for conducting cancer research, increasing prevalence of cancer, presence of market juggernauts in the region, growing awareness about non-invasive liquid biopsy products, and increasing awareness about early cancer screening. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period 2021-2031.
Global Liquid Biopsy Market Analysis & Forecast 2016 To 2022
Table of Contents
1 Product Definition
1.1 Inclusion and Exclusion
2 Market Scope
2.1 Scope of the Study
2.2 Key Questions Answered in the Report
3 Research Methodology
3.1 Global Non-Invasive Liquid Biopsy Market: Research Methodology
3.2 Data Sources
3.2.1 Primary Data Sources
3.2.2 Secondary Data Sources
3.3 Market Estimation Model
3.4 Criteria for Company Profiling
4 Market Overview
4.1 Market Definition
4.2 Emerging Applications of Non-Invasive Liquid Biopsy
4.3 Market Footprint and Growth Potential, $Million, 2020-2031
4.4 COVID-19 Impact on the Global Non-Invasive Liquid Biopsy Market
5 Industry Analysis
5.1 Overview
5.2 Legal Requirements and Framework in the U.S.
5.2.1 FDA Regulation
5.2.2 CMS Regulation
5.3 Legal Requirements and Frameworks in Europe
5.4 Legal Requirements and Frameworks in Asia-Pacific
5.4.1 China
5.4.2 Japan
5.5 Reimbursement Analysis
5.6 Return on Investment (RoI) Analysis
6 Market Dynamics
6.1 Overview
6.2 Impact Analysis
6.3 Market Drivers
6.3.1 Global Increase in Cancer Prevalence
6.3.2 Increasing Government Funding for Healthcare
6.3.3 Rise in Patient Preference for Non-Invasive Cancer Diagnosis
6.3.4 Growing Prominence of Precision Medicine in the Oncology Ecosystem
6.4 Market Restraints
6.4.1 False Negatives and Positives
6.4.2 Lack of Favorable Reimbursement Policies
6.4.3 Existing Diagnostic Confidence on Conventional Tissue-Based Biopsies
6.5 Market Opportunities
6.5.1 Amalgamation of Artificial Intelligence (AI) with Non-Invasive Liquid Biopsy
6.5.2 Massive Scope for the Adoption of Non-Invasive Liquid Biopsy Tests in the Emerging Markets
7 Competitive Landscape
7.1 Synergistic Activities
7.2 Product Approvals
7.3 Product Launches
7.4 Acquisitions
7.5 Funding and Other Activities
7.6 Market Share Analysis, 2019-2020
7.7 Growth-Share Analysis
7.7.1 Growth-Share Analysis (by Company)
7.7.2 Growth-Share Analysis (by Technology)
7.7.3 Growth-Share Analysis (by Application)
7.8 Pricing Analysis
7.8.1 Price with Sample Type
8 Global Non-Invasive Liquid Biopsy Market (by Offering), $Million, 2020-2031
8.1 Overview
8.2 Offering
8.2.1 Kits
8.2.2 Assays
8.3 Services
9 Global Non-Invasive Liquid Biopsy Market (by Sample), $Million, 2021-2031
9.1 Overview
9.2 Stool
9.3 Urine
9.4 Saliva
9.5 Other Samples
10 Global Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-2031
10.1 Overview
10.2 Oncology
10.3 Reproductive Health
10.4 Metabolic Disorders
10.5 Other Applications
11 Global Non-Invasive Liquid Biopsy Market (by Technology), $Million, 2020-2031
11.1 Overview
11.2 Polymerase Chain Reaction (PCR)
11.2.1 Real-Time PCR (RT-PCR)
11.2.2 Digital PCR (dPCR)
11.3 Sequencing
11.3.1 Next-Generation Sequencing (NGS)
11.3.2 Sanger Sequencing
11.4 Microarray
11.5 Other Technologies
12 Global Non-Invasive Liquid Biopsy Market (by End User), $Million, 2020-2031
12.1 Overview
12.2 Hospitals and Diagnostic Laboratories
12.3 Academic and Research Institutions
12.4 Other End Users
13 Global Non-Invasive Liquid Biopsy Market (by Region), $Million, 2020-2031
13.1 Overview
13.2 North America
13.2.1 U.S.
13.2.2 Canada
13.2.3 North America Non-Invasive Liquid Biopsy Market (by Application)
13.3 Europe
13.3.1 Germany
13.3.2 U.K.
13.3.3 France
13.3.4 Italy
13.3.5 Spain
13.3.6 Netherlands
13.3.7 Rest-of-Europe
13.3.8 Europe Non-Invasive Liquid Biopsy Market (by Application)
13.4 Asia-Pacific (APAC)
13.4.1 China
13.4.2 Japan
13.4.3 India
13.4.4 South Korea
13.4.5 Australia
13.4.6 Singapore
13.4.7 Rest-of-Asia-Pacific (RoAPAC)
13.4.8 Asia-Pacific Non-Invasive Liquid Biopsy Market (by Application)
13.5 Latin America (LATAM)
13.5.1 Brazil
13.5.2 Mexico
13.5.3 Rest-of-Latin America (RoLA)
13.5.4 Latin America Non-Invasive Liquid Biopsy Market (by Application)
13.6 Rest-of-the-World
13.6.1 Rest-of-the-World Non-Invasive Liquid Biopsy Market (by Application)
14 Company Profiles
14.1 Overview
14.2 Bio-Techne Corporation
14.2.1 Company Overview
14.2.2 Role of Bio-Techne Corporation in the Global Non-Invasive Liquid Biopsy Market
14.2.3 Financials
14.2.4 Key Insights About Financial Health of the Company
14.2.5 SWOT Analysis
14.3 Endress + Hauser Group
14.3.1 Company Overview
14.3.2 Role of Endress + Hauser Group in the Global Non-Invasive Liquid Biopsy Market
14.3.3 Financials
14.3.4 Key Insights About Financial Health of the Company
14.3.5 SWOT Analysis
14.4 Exact Sciences Corporation
14.4.1 Company Overview
14.4.2 Role of Exact Sciences Corporation in the Global Non-invasive Liquid Biopsy Market
14.4.3 Financials
14.4.4 Key Insights About Financial Health of the Company
14.4.5 SWOT Analysis
14.5 Lonza Group AG
14.5.1 Company Overview
14.5.2 Role of Lonza Group AG in the Global Non-Invasive Liquid Biopsy Market
14.5.3 Financials
14.5.4 Key Insights About Financial Health of the Company
14.5.5 SWOT Analysis
14.6 MDxHealth
14.6.1 Company Overview
14.6.2 Role of MDxHealth in the Global Non-Invasive Liquid Biopsy Market
14.6.3 Financials
14.6.4 Key Insights About Financial Health of the Company
14.6.5 SWOT Analysis
14.7 Merck KGaA
14.7.1 Company Overview
14.7.2 Role of Merck KGaA in the Global Non-Invasive Liquid Biopsy Market
14.7.3 Financials
14.7.4 Key Insights About Financial Health of the Company
14.7.5 SWOT Analysis
14.8 MutantDx
14.8.1 Company Overview
14.8.2 Role of MutantDx in the Global Non-Invasive Liquid Biopsy Market
14.8.3 SWOT Analysis
14.9 Norgen Biotek Corp
14.9.1 Company Overview
14.9.2 Role of Norgen Biotek Corp in the Global Non-Invasive Liquid Biopsy Market
14.9.3 SWOT Analysis
14.1 Nucleix Ltd.
14.10.1 Company Overview
14.10.2 Role of Nucleix Ltd. in the Global Non-Invasive Liquid Biopsy Market
14.10.3 SWOT Analysis
14.11 Oasis Diagnostics Corporation
14.11.1 Company Overview
14.11.2 Role of Oasis Diagnostics Corporation in the Global Non-Invasive Liquid Biopsy Market
14.11.3 SWOT Analysis
14.12 OraSure Technologies, Inc.
14.12.1 Company Overview
14.12.2 Role of OraSure Technologies, Inc. in the Global Non-Invasive Liquid Biopsy Market
14.12.3 Financials
14.12.4 Key Insights About Financial of the Company
14.12.5 SWOT Analysis
14.13 PerkinElmer Inc.
14.13.1 Company Overview
14.13.2 Role of PerkinElmer Inc. in the Global Non-Invasive Liquid Biopsy Market
14.13.3 Financials
14.13.4 Key Insights About Financial Health of the Company
14.13.5 SWOT Analysis
14.14 Predicine, Inc.
14.14.1 Company Overview
14.14.2 Role of Predicine, Inc. in the Global Non-Invasive Liquid Biopsy Market
14.14.3 SWOT Analysis
14.15 QIAGEN N.V.
14.15.1 Company Overview
14.15.2 Role of QIAGEN N.V. in the Global Non-Invasive Liquid Biopsy Market
14.15.3 Financials
14.15.4 Key Insights About Financial Health of the Company
14.15.5 SWOT Analysis
14.16 Thermo Fisher Scientific Inc.
14.16.1 Company Overview
14.16.2 Role of Thermo Fisher Scientific Inc. in the Global Non-Invasive Liquid Biopsy Market
14.16.3 Financials
14.16.4 Key Insights About Financial Health of the Company
14.16.5 SWOT Analysis
14.17 Zymo Research Corporation
14.17.1 Company Overview
14.17.2 Role of Zymo Research Corporation in the Global Non-Invasive Liquid Biopsy Market
14.17.3 SWOT Analysis
List of Tables
Table 5.1: Classification Rules of IVDs under the IVDR
Table 5.2: Key Coverage Providers for Non-Invasive Liquid Biopsy Tests
Table 6.1: Likert Scale
Table 6.2: Impact Analysis of Market Drivers
Table 6.3: Impact Analysis of Market Restraints
List of Figures
Figure 1: U.S. National Cancer Institute (NCI), Fiscal Budget Year-on-Year, 2013-2018
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Non-Invasive Liquid Biopsy Market
Figure 3: Global Non-Invasive Liquid Biopsy Market (by Offering), $Million, 2020 and 2031
Figure 4: Global Non-Invasive Liquid Biopsy Market (by Sample), $Million, 2020 and 2031
Figure 5: Global Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020 and 2031
Figure 6: Global Non-Invasive Liquid Biopsy Market (by Technology), $Million, 2020 and 2031
Figure 7: Global Non-Invasive Liquid Biopsy Market (by End User), $Million, 2020 and 2031
Figure 8: Global Non-invasive Liquid Biopsy Market Snapshot
Figure 2.1: Global Non-Invasive Liquid Biopsy Market Segmentation
Figure 3.1: Global Non-Invasive Liquid Biopsy Market: Research Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Global Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 4.2: Global Non-Invasive Liquid Biopsy Market: COVID-19 Impact Analysis
Figure 5.1: Components Considered for Clinical Evidence as per the IVDR
Figure 5.2: Global Non-Invasive Liquid Biopsy Market (Return on Investment (RoI) Analysis)
Figure 6.1: Global Cancer Burden (by Region), 2018
Figure 6.2: Increasing Government Spending for Healthcare, 2017
Figure 7.1: Share of Key Developments and Strategies, January 2017–July 2021
Figure 7.2: Share of Synergistic Activities (by Company), January 2017-June 2021
Figure 7.3: Share of Product Approvals (by Company), January 2017-July 2021
Figure 7.4: Number of Product Launches (by Company), January 2017–July 2021
Figure 7.5: Share of Acquisitions (by Company), January 2017-July 2021
Figure 7.6: Market Share Analysis for Global Non-Invasive Liquid Biopsy Market, $Million, 2019 and 2020
Figure 7.7: Growth-Share Analysis for Global Non-Invasive Liquid Biopsy Market (by Company), 2020
Figure 7.8: Growth-Share Analysis for Global Non-Invasive Liquid Biopsy Market (by Technology), 2020-2031
Figure 7.9: Growth-Share Analysis for Global Non-Invasive Liquid Biopsy Market (by Application), 2020-2031
Figure 8.1: Global Non-Invasive Liquid Biopsy Market (by Offering)
Figure 8.2: Global Non-Invasive Liquid Biopsy Market (by Offering), $Million, 2020 and 2031
Figure 8.3: Global Non-Invasive Liquid Biopsy Market (by Offering), $Million, 2020-2031
Figure 8.4: Global Non-Invasive Liquid Biopsy Market (by Offering), 2020 and 2031
Figure 8.5: Global Non-Invasive Liquid Biopsy Market (Kits), $Million, 2020-2031
Figure 8.6: Global Non-Invasive Liquid Biopsy Market (Assays), $Million, 2020-2031
Figure 8.7: Global Non-Invasive Liquid Biopsy Market (Services), $Million, 2020-2031
Figure 9.1: Global Non-Invasive Liquid Biopsy Market (by Sample), $Million, 2020-2031
Figure 9.2: Global Non-Invasive Liquid Biopsy Market (by Sample), 2020 and 2031
Figure 9.3: Global Non-Invasive Liquid Biopsy Market (Stool), $Million, 2020-2031
Figure 9.4: Global Non-Invasive Liquid Biopsy Market (Urine), $Million, 2020-2031
Figure 9.5: Global Non-Invasive Liquid Biopsy Market (Saliva), $Million, 2020-2031
Figure 9.6: Global Non-Invasive Liquid Biopsy Market (Other Samples), $Million, 2020-2031
Figure 10.1: Global Non-Invasive Liquid Biopsy Market (by Application)
Figure 10.2: Global Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-2031
Figure 10.3: Global Non-Invasive Liquid Biopsy Market (Oncology), $Million, 2020-2031
Figure 10.4: Global Non-Invasive Liquid Biopsy Market (Reproductive Health), $Million, 2020-2031
Figure 10.5: Global Non-Invasive Liquid Biopsy Market (Metabolic Disorders), $Million, 2020-2031
Figure 10.6: Global Non-Invasive Liquid Biopsy Market (Other Applications), $Million, 2020-2031
Figure 11.1: Global Non-Invasive Liquid Biopsy Market (by Technology)
Figure 11.2: Global Non-Invasive Liquid Biopsy Market (by Technology), 2020 and 2031
Figure 11.3: Global Non-Invasive Liquid Biopsy Market (PCR), $Million, 2020-2031
Figure 11.4: Global Non-Invasive Liquid Biopsy Market (PCR), 2020 and 2031
Figure 11.5: Global Non-Invasive Liquid Biopsy Market (RT-PCR, by PCR), $Million, 2020-2031
Figure 11.6: Global Non-Invasive Liquid Biopsy Market (dPCR, by PCR), $Million, 2020-2031
Figure 11.7: Global Non-Invasive Liquid Biopsy Market (Sequencing), $Million, 2020-2031
Figure 11.8: Global Non-Invasive Liquid Biopsy Market (Sequencing), 2020 and 2031
Figure 11.9: Global Non-Invasive Liquid Biopsy Market (NGS, by Sequencing), $Million, 2020-2031
Figure 11.10: Global Non-Invasive Liquid Biopsy Market (Sanger Sequencing, by Sequencing), $Million, 2020-2031
Figure 11.11: Global Non-Invasive Liquid Biopsy Market (Microarray), $Million, 2020-2031
Figure 11.12: Global Non-Invasive Liquid Biopsy Market (Other Technologies), $Million, 2020-2031
Figure 12.1: Global Non-Invasive Liquid Biopsy Market (by End User)
Figure 12.2: Global Non-Invasive Liquid Biopsy Market (by End User), $Million, 2020-2031
Figure 12.3: Global Non-Invasive Liquid Biopsy Market (Hospitals and Diagnostic Laboratories), $Million, 2020-2031
Figure 12.4: Global Non-Invasive Liquid Biopsy Market (Academic and Research Institutions), $Million, 2020-2031
Figure 12.5: Global Non-Invasive Liquid Biopsy Market (Other End Users), $Million, 2020-2031
Figure 13.1: Global Non-Invasive Liquid Biopsy Market (by Region): Market Snapshot
Figure 13.2: Global Non-Invasive Liquid Biopsy Market (by Region), $Million, 2020-2031
Figure 13.3: North America Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.4: North America: Market Dynamics
Figure 13.5: North America Non-Invasive Liquid Biopsy Market (by Country), $Million, 2020-2031
Figure 13.6: U.S. Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.7: Canada Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.8: North America Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-2031
Figure 13.9: Europe Non-invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.10: Europe: Market Dynamics
Figure 13.11: Europe Non-Invasive Liquid Biopsy Market (by Country), $Million, 2020-2031
Figure 13.12: Germany Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.13: U.K. Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.14: France Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.15: Italy Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.16: Spain Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.17: Netherlands Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.18: Rest-of-Europe Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.19: Europe Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-2031
Figure 13.20: Asia-Pacific Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.21: APAC Non-Invasive Liquid Biopsy Market (by Country), $Million, 2020-2031
Figure 13.22: China Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.23: Japan Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.24: India Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.25: South Korea Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.26: Australia Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.27: Singapore Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.28: RoAPAC Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.29: APAC Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-2031
Figure 13.30: Latin America Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.31: Latin America: Market Dynamics
Figure 13.32: Latin America Non-Invasive Liquid Biopsy Market (by Country), $Million, 2020-2031
Figure 13.33: Brazil Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.34: Mexico Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.35: RoLA Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.36: LATAM Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-2031
Figure 13.37: Rest-of-the-World Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
Figure 13.38: Rest-of-the-World Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-2031
Figure 14.1: Total Number of Companies Profiled
Figure 14.2: Bio-Techne Corporation: Service Portfolio
Figure 14.3: Bio-Techne Corporation: Overall Financials, 2018-2020
Figure 14.4: Bio-Techne Corporation: Revenue (by Segment), 2018-2020
Figure 14.5: Bio-Techne Corporation: Revenue (by Region), 2018-2020
Figure 14.6: Bio-Techne Corporation: R&D Expenditure, 2018-2020
Figure 14.7: Bio-Techne Corporation: SWOT Analysis
Figure 14.8: Endress + Hauser Group: Product Portfolio
Figure 14.9: Endress + Hauser Group: Overall Financials, 2018-2020
Figure 14.10: Endress + Hauser Group: Revenue (by Segment), 2018-2020
Figure 14.11: Endress + Hauser Group: Revenue (by Region), 2018-2020
Figure 14.12: Endress + Hauser Group: R&D Expenditure, 2018-2020
Figure 14.13: Endress + Hauser Group: SWOT Analysis
Figure 14.14: Exact Sciences Corporation: Service Portfolio
Figure 14.15: Exact Sciences Corporation: Overall Financials, 2018-2020
Figure 14.16: Exact Sciences Corporation: Revenue (by Segment), 2018-2020
Figure14.17: Exact Sciences Corporation: Revenue (by Region), 2018-2020
Figure 14.18: Exact Sciences Corporation: R&D Expenditure, 2018-2020
Figure 14.19: Exact Sciences Corporation: SWOT Analysis
Figure 14.20: Lonza Group AG: Product Portfolio
Figure 14.21: Lonza Group AG: Overall Financials, 2018-2020
Figure 14.22: Lonza Group AG: Revenue (by Segment), 2018-2020
Figure 14.23: Lonza Group AG: Revenue (by Region), 2018-2020
Figure 14.24: Lonza Group AG: R&D Expenditure, 2018-2020
Figure 14.25: Lonza Group AG: SWOT Analysis
Figure 14.26: MDxHealth: Service Portfolio
Figure 14.27: MDxHealth: Overall Financials, 2018-2020
Figure 14.28: MDxHealth: Revenue (by Segment), 2018-2020
Figure 14.29: MDxHealth: Revenue (by Region), 2018-2020
Figure 14.30: MDxHealth: R&D Expenditure, 2018-2020
Figure 14.31: MDxHealth: SWOT Analysis
Figure 14.32: Merck KGaA: Product Portfolio
Figure 14.33: Merck KGaA: Overall Financials, 2018-2020
Figure 14.34: Merck KGaA: Revenue (by Segment), 2018-2020
Figure 14.35: Merck KGaA: Revenue (by Region), 2018-2020
Figure 14.36: Merck KgaA: R&D Expenditure, 2018-2020
Figure 14.37: Merck KGaA: SWOT Analysis
Figure 14.38: MutantDx: Product Portfolio
Figure 14.39: MutantDx: SWOT Analysis
Figure 14.40: Norgen Biotek Corp: Product Portfolio
Figure 14.41: Norgen Biotek Corp: SWOT Analysis
Figure 14.42: Nucleix Ltd.: Product Portfolio
Figure 14.43: Nucleix Ltd.: SWOT Analysis
Figure 14.44: Oasis Diagnostics Corporation: Product Portfolio
Figure 14.45: Oasis Diagnostics Corporation: SWOT Analysis
Figure 14.46: OraSure Technologies, Inc.: Product Portfolio
Figure 14.47: OraSure Technologies, Inc.: Overall Financials, 2018-2020
Figure 14.48: OraSure Technologies, Inc.: Revenue (by Segment), 2018-2020
Figure 14.49: OraSure Technologies, Inc.: Revenue (by Molecular Solutions), 2019-2020
Figure 14.50: OraSure Technologies, Inc.: Revenue (by Region), 2018-2020
Figure 14.51: OraSure Technologies, Inc.: R&D Expenditure, 2018-2020
Figure 14.52: OraSure Technologies, Inc.: SWOT Analysis
Figure 14.53: PerkinElmer Inc.: Product Portfolio
Figure 14.54: PerkinElmer Inc.: Overall Financials, 2018-2020
Figure 14.55: PerkinElmer Inc.: Revenue (by Segment), 2018-2020
Figure 14.56: PerkinElmer Inc.: Revenue (by Region), 2018-2020
Figure 14.57: PerkinElmer Inc.: R&D Expenditure, 2018-2020
Figure 14.58: PerkinElmer Inc.: SWOT Analysis
Figure 14.59: Predicine, Inc.: Service Portfolio
Figure 14.60: Predicine, Inc.: SWOT Analysis
Figure 14.61: QIAGEN N.V.: Product Portfolio
Figure 14.62: QIAGEN N.V.: Overall Financials, 2018-2020
Figure 14.63: QIAGEN N.V.: Revenue (by Segment), 2018-2020
Figure 14.64: QIAGEN N.V.: Revenue (by Region), 2018-2020
Figure 14.65: QIAGEN N.V.: R&D Expenditure, 2018-2020
Figure 14.66: QIAGEN N.V.: SWOT Analysis
Figure 14.67: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 14.68: Thermo Fisher Scientific, Inc.: Overall Financials, 2018-2020
Figure 14.69: Thermo Fisher Scientific Inc.: Revenue (by Segment): 2018-2020
Figure 14.70: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020
Figure 14.71: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
Figure 14.72: Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 14.73: Zymo Research Corporation: Product Portfolio
Figure 14.74: Zymo Research Corporation: SWOT Analysis
